This may reflect the difficulty in Quisinostat cost recruiting and retaining patients with this liver disease The significant heterogeneity precluded pooling of results. AG-881 Results are presented separately for EPZ015666 nmr single markers (Table 2) and for marker panels (Table 3) in the identification of cirrhosis (F4 METAVIR) cirrhosis, /severe fibrosis (F3/F4

METAVIR) and ‘significant’ fibrosis (F2-4-Metavir). Test AUROCS Cut off Sens Spec PPV NPV LR+ -LR (95% CI) (95% CI) Cirrhosis Poynard [16] 1991 624 PGA n/r

6 85 85 70 93 5.6 (4.5 7.01) 0.18 (0.12,0.25) Cirrhosis Tran [19] 2000 146 Tran n/r   76 99 98 86 66.8 (9.5,471.2) 0.24 (0.15,0.37) Cirrhosis Naveau [25] 2005 221 Fibrotest 0.95 (0.94, 0.96) 0.3 84 41 39 85 1.4 (1.2,1.7) 0.39 (0.2,0.70) 0.7 60 72 49 80 2.1 (1.6,2.9) 0.55 (0.40,0.75) Cirrhosis Lieber [27] 2006 1034 APRI 0.79 >2.0 17 86 56 50 1.2 (0.9,1.6) 1.0 (0.92,1.02) Cirrhosis Nguyen –Khac [28] 2008 103 Fibrotest 0.84 (0.72,0.97) n/r n/r n/r n/r n/r n/r n/r Fibrometer 0.85 (0.74,0.96) n/r n/r n/r n/r Amisulpride n/r n/r n/r Hepascore 0.76 (0.63,0.90) n/r n/r n/r n/r n/r n/r n/r APRI 0.56 (0.38,0.73) n/r n/r n/r n/r n/r n/r n/r PGA 0.89 (0.82 0.97) n/r n/r n/r n/r n/r n/r n/r PGAA 0.83 (0.73-0.93) n/r n/r n/r n/r n/r n/r n/r Cirrhosis Naveau [30] 2009 218 Fibrotest 0.94 (0.90,0.96) 0.56 90 n/r n/r n/r n/r n/r 0.78 n/r 90 n/r n/r n/r n/r >0.30 100 50 47 100 2.0 0.50 >0.70 87 86 73 94 6.2 0.16 Fibrometer 0.94 (0.90,0.97) 0.92 90 n/r n/r n/r n/r n/r 0.997 n/r 90 n/r n/r n/r n/r >0.50 99 62 54 99 2.6 0.38 >1.0 88 88 76 94 7.3 0.14 Hepascore 0.92 (0.87,0.97) 0.97 90 n/r n/r n/r n/r n/r 0.99 n/r 90 n/r n/r n/r n/r Forns 0.38 (0.27,0.47) n/r n/r n/r n/r n/r n/r n/r APRI 0.67 (0.59,0.75) n/r n/r n/r n/r n/r n/r n/r FIB4 0.80 (0.72,0.86) n/r n/r n/r n/r n/r n/r n/r F012vs 34 Severe Rosenberg [24] 2004 64 ELF 0.94 (0.84, 1.00) 0.087 100 17 75 100 1.2 (1.1, 1.4) 0.06 (0.01, 0.3) 0.